Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.41 |
| ▸ | GNA15 | P30679 | 1/20 | 0.41 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.41 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.41 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.41 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | PPARD | Q03181 | 4/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562175 | 0.96 | FFAR1 (0.42) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL562539 | 0.96 | FFAR1 (0.42) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL563210 | 0.96 | FFAR1 (0.42) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL10203936 | 0.94 | FFAR1 (0.44) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL10203955 | 0.93 | FFAR1 (0.42) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL10203935 | 0.92 | FFAR1 (0.41) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL562098 | 0.92 | CD274 (0.43) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL563361 | 0.92 | CD274 (0.43) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL563287 | 0.92 | CD274 (0.43) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL10203934 | 0.90 | FFAR1 (0.53) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423176-A1 | CARBOXYLIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | claimed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | claimed |
| EP-2423176-A1 | CARBOXYLIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010123016-A1 | CARBOXYLIC ACID COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | GPR119, GPR65, GPR55 | FFAR1 23/4885GNA15 1220/4885SLC10A1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.